Skip to main content

Table 2 Index medication and use of medications following the index date for unweighted and weighted populations

From: Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

 

Unweighted populations

Weighted populationsa

CANA

DPP-4

P-valueb

CANA

DPP-4

P-valueb

N = 10,702

N = 17,679

N = 13,793

N = 14,588

Observation period, days, mean ± SD [median]

303 ± 224 [266]

420 ± 268 [404]

<0.001

343 ± 250 [305]

372 ± 259 [338]

<0.001

Duration of treatment, days, mean ± SD [median]

245 ± 199 [200]

314 ± 237 [259]

<0.001

267 ± 218 [211]

282 ± 223 [224]

<0.001

CANA dose prescribed at index datec, n (%)

 100 mg

6,725 (62.8)

-

 

8,216 (59.6)

-

 

 300 mg

3,681 (34.4)

-

 

3,964 (28.7)

-

 

 50 mg

230 (2.1)

-

 

862 (6.3)

-

 

 with metformin 500 mg

73 (0.7)

-

 

275 (2.0)

-

 

 with metformin 1000 mg

159 (1.5)

-

 

591 (4.3)

-

 

 150 mg

328 (3.1)

-

 

1,081 (7.8)

-

 

 with metformin 500 mg

87 (0.8)

-

 

334 (2.4)

-

 

 with metformin 1000 mg

243 (2.3)

-

 

752 (5.5)

-

 

DPP-4 dose prescribed at index datec, n (%)

 Alogliptin

-

312 (1.8)

 

-

238 (1.6)

 

 6.25 mg

-

1 (0.0)

 

-

1 (0.0)

 

 12.5 mg

-

104 (0.6)

 

-

61 (0.4)

 

 25 mg

-

211 (1.2)

 

-

178 (1.2)

 

 Linagliptin

-

2,530 (14.3)

 

-

2,187 (15.0)

 

 2.5 mg

-

266 (1.5)

 

-

152 (1.0)

 

 5 mg

-

2,268 (12.8)

 

-

2,037 (14.0)

 

 Saxagliptin

-

1,986 (11.2)

 

-

1,532 (10.5)

 

 2.5 mg

-

559 (3.2)

 

-

389 (2.7)

 

 5 mg

-

1,443 (8.2)

 

-

1,154 (7.9)

 

 Sitagliptin

-

12,980 (73.4)

 

-

10,740 (73.6)

 

 25 mg

-

461 (2.6)

 

-

399 (2.7)

 

 50 mg

-

4,934 (27.9)

 

-

3,443 (23.6)

 

 100 mg

-

7,691 (43.5)

 

-

6,971 (47.8)

 

New antihyperglycemic agentsd, n (%)

2,868 (26.8%)

8,543 (48.3%)

<0.001

4,182 (30.3%)

6,616 (45.4%)

<0.001

 Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors

524 (4.9%)

3,720 (21.0%)

<0.001

710 (5.1%)

2,907 (19.9%)

<0.001

 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

980 (9.2%)

2,034 (11.5%)

<0.001

1,565 (11.3%)

1,566 (10.7%)

0.100

 Glucagon-like peptide 1 (GLP-1) agonists

564 (5.3%)

1,707 (9.7%)

<0.001

819 (5.9%)

1,291 (8.8%)

<0.001

 Insulins

454 (4.2%)

1,818 (10.3%)

<0.001

805 (5.8%)

1,260 (8.6%)

<0.001

 Sulfonylureas derivatives

399 (3.7%)

1,808 (10.2%)

<0.001

585 (4.2%)

1,335 (9.2%)

<0.001

 Biguanides

280 (2.6%)

975 (5.5%)

<0.001

472 (3.4%)

701 (4.8%)

<0.001

 Thiazolidinediones

239 (2.2%)

693 (3.9%)

<0.001

366 (2.7%)

505 (3.5%)

<0.001

 Meglitinide Analogues

57 (0.5%)

175 (1.0%)

<0.001

102 (0.7%)

130 (0.9%)

0.152

 Other

42 (0.4%)

67 (0.4%)

0.859

47 (0.3%)

56 (0.4%)

0.594

 Alpha-Glucosidase Inhibitors

20 (0.2%)

66 (0.4%)

0.006

24 (0.2%)

53 (0.4%)

0.002

 Amylin Analogs

5 (0.0%)

5 (0.0%)

0.423

5 (0.0%)

4 (0.0%)

0.713

 Dopamine Receptor Agonists

4 (0.0%)

8 (0.0%)

0.755

3 (0.0%)

6 (0.0%)

0.408

  1. CANA canagliflozin, DPP-4 dipeptidyl peptidase-4
  2. Notes:
  3. aWeighted populations were obtained using inverse probability of treatment weighting based on the propensity score of being treated with CANA. The propensity score was estimated using a multivariate logit regression and baseline covariates included age, gender, US region, race/ethnicity, Quan-Charlson comorbidity index, use of fixed-dose combination at index date, number of visits, closest HbA1c measurement to index date, closest BMI measurement to index date, obesity diagnosis, and quarter of the index date. The number of patients reported for weighted populations corresponds to the sum of weights attributed to patients in each cohort. The sum of weights across both cohorts gives the same total number of patients before (10,702 + 17,679 = 28,381) and after weighting (13,793 + 14,588 = 28,381)
  4. b P-values were estimated using chi-square tests or weighted chi-square tests for categorical variables and t-tests or weighted t-tests for continuous variables
  5. cThere may be more than one prescription at the index date; therefore, categories are not mutually exclusive
  6. dEvaluated on or after the index date
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us